‹ Screener

Burning Rock Biotech Ltd

BNR · Services-Medical Laboratories · EDGAR filings ↗

Reference price $17.36 — last insider purchase, 2026-03-31 (estimated from the dated SEC Form 4 price — not a live quote)

Grade

C55

Well-capitalized Chinese precision-oncology testing leader, still lossmaking but with sharply narrowing losses.

Strengths

Risks

Notable findings

Key metrics

Gross margin
74.7%
Operating margin
-10.2%
Net margin
-10.3%
Return on equity
-10.3%
Return on assets
-6.7%
Revenue growth (QoQ)
9.2%
Current ratio
3.0×
Free cash flow
-$5M
EBITDA
-$5M
Tangible book value
$77M
Cash & investments
$68M
Cash runway
57q
Stock comp / revenue
2.6%

Insider transactions · last 18 months

DateInsiderTypeSharesPrice
2026-03-31Han YushengBuy315K$17.36

All non-derivative Form 4 activity (SEC), newest first.

Recent filings

FormFiledPeriodAccession
20-F2026-04-282025-12-310001193125-26-183377 ↗
20-F2025-04-292024-12-310001193125-25-101753 ↗
20-F2024-04-292023-12-310001193125-24-119655 ↗
20-F2023-04-202022-12-310001193125-23-108289 ↗
20-F2022-04-292021-12-310001193125-22-133522 ↗
20-F2021-03-232020-12-310001193125-21-090543 ↗